|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Modern management of rectal cancer: A 2006 update显示文摘The goal of this review is to outline some of the important surgical issues surrounding the management of patients with early (T1/T2 and NO), as well as locally advanced (T3/T4 and/or N1) rectal cancer. Surgery for rectal cancer continues to develop towards the ultimate goals of improved local control and overall survival, maintaining quality of life, and preserving sphincter, genitourinary, and sexual function. Information concerning the depth of tumor penetration through the rectal wall, lymph node involvement, and presence of distant metastatic disease is of crucial importance when planning a curative rectal cancer resection. Preoperative staging is used to determine the indication for neoadjuvant therapy as well as the indication for local excision versus radical cancer resection. Local excision is likely to be curative in most patients with a primary tumor which is limited to the submucosa (T1N0M0), without high-risk features and in the absence of metastatic disease. In appropriate patients, minimally invasive procedures, such as local excision, TEM, and laparoscopic resection allow for improved patient comfort, shorter hospital stays, and earlier return to preoperative activity level. Once the tumor invades the muscularis propria (T2), radical rectal resection in acceptable operative candidates is recommended. In patients with transmural and/or node positive disease (T3/T4 and/or N1) with no distant metastases, preoperative chemoradiation followed by radical resection according to the principles of TME has become widely accepted. During the planning and conduct of a radical operation for a locally advanced rectal cancer, a number of surgical management issues are considered, including: (1) total mesorectal excision (TME); (2) autonomic nerve preservation (ANP); (3) circumferential resection margin (CRM); (4) distal resection margin; (5) sphincter preservation and options for restoration of bowel continuity; (6) laparoscopic approaches; and (7) postoperative quality of life. | Glen C Balch Alex De Meo Jose G Guillem | 2006 | World Journal of Gastroenterology2006，12，20： | 26 |
| 2 | Behavior-based formation control for multirobot teams显示文摘 | Balch T Arkin R C | 1998 | IEEE Trans Robot Automat1998，14，6： | 2 |
| 3 | Communication of behavorial state in multi-agent retrieval tasks显示文摘 | Ronald C Arkin Tucker Balch Elizabeth Nitz | 2003 | Robotics and Automation2003，，3： | 1 |
| 4 | Identification and characterization of ovarian Cancer-initiating cells from primary human tumors显示文摘 | Zhang Shu Balch C Michael W | 2008 | Cancer Res2008，68，11： | 1 |
| 5 | Identification and characterization of ovarian cancer-initiating cells from primary human tumors 显示文摘 | Zhang S Balch C Chan MW | 2008 | Cancer Res2008，68，11： | 1 |
| 6 | The epigenetics of ovarian cancer drug resistance and resensitization显示文摘 | Balch C Huang TH Brown R | 2004 | Am J Obstet Gynecol2004，191，5： | 1 |
| 7 | Load partitioning in aluminum syntactic foams containing ceramic microspheres显示文摘 | BALCH D K DUNAND D C | 2006 | Acta Materialia2006，54，6： | 1 |
| 8 | Identification and charac-terization of ovarian cancer-initiating cells from primary hu-man tumors显示文摘 | Zhang S Balch C Chan M W | 2008 | Cancer Res2008，68，11： | 1 |
| 9 | Identification and characterization of ovarian cancer-initiating cells from primary human tumors 显示文摘 | Zhang S Balch C Chan MW | 2008 | Cancer Res2008，68，11： | 1 |
| 10 | Minireview:epigenetic changes in ovarian cancer显示文摘 | Balch C Fang F Matei DE | 2009 | Endocrinology2009，150，9： | 1 |
| 11 | A phase II ranomized,double-blind mutiinstitational trial of vacciniamelanoma oncolysate: active specific immunotherapy for patientswith stage Ⅱ melanonm显示文摘 | Wallack M K Sivanadham M Balch C M et at | 1995 | Cancer1995，75，17： | 1 |
| 12 | Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer显示文摘 | Balch C Yan P Craft T | 2005 | Mol Cancer Ther2005，4，10： | 1 |
| 13 | Identification and characterization of ovarian cancer-initiating cells from primal'y human tumors 显示文摘 | Zhang S Balch C Chan MW | 2008 | Cancer Res2008，68，11： | 1 |
| 14 | The glycoprotein that is transported between successive compartments of the Golgi in a cell-free system resides in stacks of cistemae 显示文摘 | BRAELL W A BALCH W E DOBBERTIN D C | 1984 | Cell1984，39，3： | 1 |
| 15 | Behavior-based formation control for multirobot teams显示文摘 | Tucker Balch Ronald C Arkin | 1998 | IEEE Transactions on Robotics and Automation1998，14，： | 1 |
| 16 | Behavior-based formation control for multirobot teams显示文摘 | Balch T Arkin R C | 1998 | IEEE Transactions on Robotics and Automa- tion1998，14，6： | 1 |
| 17 | Identification and characterization of ovarian cancer-initiating cells from primary human tumors显示文摘 | Zhang S Balch C Chan M | 2008 | Cancer Res2008，68，11： | 1 |
| 18 | Plasticity and damage in aluminum syntactic foams deformed under dynamic and quasi-static conditions 显示文摘 | BALCH D K O'DWYER J G DAVIS G R CADY C M GRAY G T DUNAND D C | 2005 | Materials Science and Engineering A2005，391，12： | 1 |
| 19 | Prognostic DNA methylation biomarkers in ovarian cancer显示文摘 | Wei SH Balch C Paik HH | 2006 | Clin Cancer Res2006，12，9： | 1 |
| 20 | Final version of the A-merican Joint Committee on cancer staging system for cutaneous melanoma 显示文摘 | Balch C M Buzaid A C Soong SJ | 2001 | J Clin Oneol2001，19，16： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员